Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $21.20, but opened at $21.92. Chugai Pharmaceutical shares last traded at $21.5112, with a volume of 1,627 shares traded.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the stock. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on CHGCY
Chugai Pharmaceutical Trading Up 1.5%
The firm has a fifty day simple moving average of $20.77 and a 200-day simple moving average of $24.61.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported $0.27 earnings per share for the quarter. The firm had revenue of $2.54 billion during the quarter, compared to analysts’ expectations of $2.29 billion. As a group, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 1.00 EPS for the current year.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.
The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.
Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.
Further Reading
- Five stocks we like better than Chugai Pharmaceutical
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
